Liquidia Settles All United Therapeutics Litigation for $380.7 Million, Keeps Yutrepia on Market

05:47 AM EDT, 10/14/2026 (MT Newswires) -- Liquidia (LQDA) said late Tuesday it ended all six pending lawsuits with United Therapeutics (UTHR) in a deal that keeps its Yutrepia treatment for pulmonary arterial hypertension on the market and has net costs of $380.7 million through 2027. United Therapeutics will receive $175 million within 30 business days, then $145.4 million in two equal installments due Jan. 31, 2027, and April 30, 2027, and Liquidia will pay a further $60.3 million this month to outside parties with claims tied to a related antitrust case, the company said. A Delaware federal court ruled Sept. 30 that a United Therapeutics patent covering Yutrepia use for pulmonary hypertension regarding lung disease was valid and infringed, and Liquidia agreed to drop that use from the label and not appeal, Liquidia said. Preliminary Q3 net sales of Yutrepia were $222.7 million, and cash stood at $396.1 million as of Sept. 30, and the company expects to fund the settlement from sales and cash without raising new money, it added. Shares of Liquidia were up over 49% in Wednesday premarket activity. Price: 40.10, Change: +13.29, Percent Change: +49.57